Termination of Declaration Authorizing Emergency Use of Drug and Biological Products During the COVID-19 Pandemic
The termination of the COVID-19 emergency use declaration does not directly affect cosmetics or personal care products under MoCRA. However, businesses that also manufacture or distribute drug or biological products under EUAs must cease use and transition to standard approvals.
Aforeworn detected this change in the Cosmetics & Personal-Care (MoCRA) space on July 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Cosmetics and personal care businesses that also manufacture or distribute drug or biological products under COVID-19 EUAs should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately upon publication (July 2, 2026).. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Cosmetics & Personal-Care (MoCRA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The HHS Secretary terminated the declaration authorizing emergency use of certain drug and biological products during the COVID-19 pandemic, effective immediately.
Who it affects
Cosmetics and personal care businesses that also manufacture or distribute drug or biological products under COVID-19 EUAs
What you must do
If your business holds an EUA for a drug or biological product, you must stop distributing the product under that EUA and either obtain full FDA approval or cease distribution.
Deadline
Immediately upon publication (July 2, 2026).
Never miss a change like this again
Aforeworn watches Cosmetics & Personal-Care (MoCRA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Cosmetics & Personal-Care (MoCRA)
- FDA Launches One-Day Inspectional Assessments to Strengthen and Expand Oversight
- FDA Grants Seventh Approval under the National Priority Voucher Pilot Program
- FDA Issues Guidance to Improve Collection of Pregnancy Safety Data for Drugs and Biologics
- FDA Expands AI Capabilities and Completes Data Platform Consolidation
- FDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV) Infection